Last 12 months
Inside the activity.
1 purchase rows · 33 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 5 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 19 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC |
KOCH KEVINDirector · President and CEO
|
Exercise / conversionCommon Stock | 21,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 2 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 20:52 UTC |
KOCH KEVINDirector · President and CEO
|
Exercise / conversionCommon Stock | 17,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001185829-26-000001 · primarydocument.xml · nonDerivative · entry 1 KOCH KEVIN · CIK 0001185829 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:40 UTC Amendment |
Russell Alan JDirector · Chief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001853529-26-000003 · primarydocument.xml · derivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:39 UTC Amendment |
Derakhshan BehradChief Business Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001853109-26-000002 · primarydocument.xml · derivative · entry 1 Derakhshan Behrad · CIK 0001853109 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:41 UTC Amendment |
Nofi MichaelChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 48,750 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001705477-26-000002 · primarydocument.xml · derivative · entry 1 Nofi Michael · CIK 0001705477 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,750 Underlying: Common Stock · 48,750 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| August 12, 2026 Filed Aug 17, 2026 22:41 UTC Amendment | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001644087-26-000006 · primarydocument.xml · derivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
|
| August 12, 2026 Filed Aug 17, 2026 22:40 UTC Amendment |
MOORE JOHN RGeneral Counsel
|
GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001191702-26-000002 · primarydocument.xml · derivative · entry 1 MOORE JOHN R · CIK 0001191702 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-08-12 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 01, 2026 Filed Jul 1, 2026 23:46 UTC |
Fox Jonathan CDirector
|
GrantCommon Stock | 319 | $0.00 | $0.00 |
DisclosureSEC source: 0001655016-26-000004 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,833 Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC |
Russell Alan JDirector · Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 69,648 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · derivative · entry 6 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,077,717 Underlying: Common Stock · 69,648 shares Expires 2032-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on July 27, 2017, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC |
Russell Alan JDirector · Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 130,352 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · derivative · entry 5 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 130,352 shares Expires 2028-08-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 10, 2018, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC |
Russell Alan JDirector · Chief Scientific Officer
|
SaleCommon Stock | 69,648 | $39.41 | $2,744,751.07 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 4 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,555 F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.905, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC |
Russell Alan JDirector · Chief Scientific Officer
|
SaleCommon Stock | 130,352 | $39.41 | $5,136,650.91 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 3 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,203 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $40.81, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC |
Russell Alan JDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 69,648 | $0.18 | $12,536.64 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 2 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:21 UTC |
Russell Alan JDirector · Chief Scientific Officer
|
Exercise / conversionCommon Stock | 130,352 | $0.45 | $58,658.40 |
DisclosureSEC source: 0001853529-26-000001 · primarydocument.xml · nonDerivative · entry 1 Russell Alan J · CIK 0001853529 · Director · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 107 shares purchased on November 15, 2025 and 1,048 shares purchased on May 15, 2026 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
| June 05, 2026 Filed Jun 16, 2026 22:19 UTC |
Edris BadreddinDirector
|
GrantStock Option (Right to Buy) · Derivative | 8,188 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001786966-26-000003 · primarydocument.xml · derivative · entry 2 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,188 Underlying: Common Stock · 8,188 shares Expires 2036-06-05 F2 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jun 16, 2026 22:19 UTC |
Edris BadreddinDirector
|
GrantRestricted Stock Units · Derivative | 5,619 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001786966-26-000003 · primarydocument.xml · derivative · entry 1 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,619 Underlying: Common Stock · 5,619 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Restricted Stock Units granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jun 16, 2026 22:16 UTC |
Martin Christopher NathanDirector
|
GrantStock Options (Right to buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0002097992-26-000001 · primarydocument.xml · derivative · entry 1 Martin Christopher Nathan · CIK 0002097992 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jun 16, 2026 22:15 UTC |
Fox Jonathan CDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001655016-26-000003 · primarydocument.xml · derivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jun 17, 2026 21:14 UTC |
Brege LauraDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001365619-26-000004 · primarydocument.xml · derivative · entry 1 Brege Laura · CIK 0001365619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jun 17, 2026 20:49 UTC |
Thompson Peter A.Director · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001357522-26-000001 · primarydocument.xml · derivative · entry 1 Thompson Peter A. · CIK 0001357522 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jun 17, 2026 20:46 UTC |
Morris ArleneDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001362520-26-000001 · primarydocument.xml · derivative · entry 1 Morris Arlene · CIK 0001362520 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of stockholder. Read SEC document |
| June 05, 2026 Filed Jul 17, 2026 20:24 UTC |
ROOT JONATHAN DDirector
|
GrantStock Option (Right to Buy) · Derivative | 16,377 | $0.00 Strike: $35.59 | $0.00 |
DisclosureSEC source: 0001710072-26-000001 · primary_doc.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,377 Underlying: Common Stock · 16,377 shares Expires 2036-06-05 F1 · derivative.exercise_date: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders. Read SEC document |
| May 05, 2026 Filed May 5, 2026 17:15 UTC | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · derivative · entry 4 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 50,000 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
|
| May 05, 2026 Filed May 5, 2026 17:15 UTC | SaleCommon Stock | 50,000 | $38.57 | $1,928,400.00 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · nonDerivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F3 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $39.96 inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| May 05, 2026 Filed May 5, 2026 17:15 UTC | Exercise / conversionCommon Stock | 50,000 | $7.08 | $354,000.00 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,367 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| May 04, 2026 Filed May 5, 2026 17:15 UTC | SaleCommon Stock | 5,230 | $31.29 | $163,662.91 |
DisclosureSEC source: 0001644087-26-000004 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,367 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.72 to $31.66, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| April 01, 2026 Filed Apr 2, 2026 17:01 UTC | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,662 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001644087-26-000003 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 28,662 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
|
| April 01, 2026 Filed Apr 2, 2026 17:01 UTC | SaleCommon Stock | 28,662 | $32.31 | $926,095.02 |
DisclosureSEC source: 0001644087-26-000003 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.60, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| April 01, 2026 Filed Apr 2, 2026 17:01 UTC | Exercise / conversionCommon Stock | 28,662 | $7.08 | $202,926.96 |
DisclosureSEC source: 0001644087-26-000003 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| April 01, 2026 Filed Apr 3, 2026 18:12 UTC |
Fox Jonathan CDirector
|
GrantCommon Stock | 339 | $0.00 | $0.00 |
DisclosureSEC source: 0001655016-26-000002 · primarydocument.xml · nonDerivative · entry 1 Fox Jonathan C · CIK 0001655016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,514 Read SEC document |
| March 31, 2026 Filed Mar 31, 2026 23:33 UTC | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,338 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001644087-26-000002 · primarydocument.xml · derivative · entry 3 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 153,662 Underlying: Common Stock · 21,338 shares Expires 2033-08-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date. Read SEC document |
|
| March 31, 2026 Filed Mar 31, 2026 23:33 UTC | SaleCommon Stock | 21,338 | $32.12 | $685,308.28 |
DisclosureSEC source: 0001644087-26-000002 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,597 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| March 31, 2026 Filed Mar 31, 2026 23:33 UTC | Exercise / conversionCommon Stock | 21,338 | $7.08 | $151,073.04 |
DisclosureSEC source: 0001644087-26-000002 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| March 27, 2026 Filed Mar 30, 2026 21:32 UTC | SaleCommon Stock | 6,735 | $30.98 | $208,635.48 |
DisclosureSEC source: 0001644087-26-000001 · primarydocument.xml · nonDerivative · entry 2 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,597 F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
|
| March 27, 2026 Filed Mar 30, 2026 21:32 UTC | SaleCommon Stock | 9,623 | $30.98 | $298,099.37 |
DisclosureSEC source: 0001644087-26-000001 · primarydocument.xml · nonDerivative · entry 1 Donovan Joanne M. · CIK 0001644087 · CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,332 F1 · shares: The shares sold were acquired through multiple purchases under the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan on May 15, 2022 (1,392 shares), November 15, 2022 (1,406 shares), May 15, 2023 (1,451 shares), November 15, 2023 (1,751 shares), May 15, 2024 (1,803 shares), and November 15, 2024 (1,820 shares). F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $30.49 to $31.68, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 594 shares purchased on November 17,2025 pursuant to the Edgewise Therapeutics, Inc. 2021 Employee Stock Purchase Plan. Read SEC document |
|
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 13,690 | $0.00 Strike: $0.39 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 15 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,690 shares Expires 2028-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 17,236 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 14 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,236 shares Expires 2029-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 7,605 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 13 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,605 shares Expires 2030-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 66,477 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 12 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,477 shares Expires 2031-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,463 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · derivative · entry 11 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,463 shares Expires 2030-12-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
SaleCommon Stock | 66,477 | $29.44 | $1,957,082.88 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 10 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,820 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
SaleCommon Stock | 10,463 | $29.44 | $308,030.72 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 9 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,297 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
SaleCommon Stock | 7,605 | $29.44 | $223,891.20 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 8 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,760 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
SaleCommon Stock | 17,236 | $29.44 | $507,427.84 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 7 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,365 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
SaleCommon Stock | 13,690 | $29.44 | $403,033.60 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 6 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,601 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on September 24, 2025. F2 · price: The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.77, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionCommon Stock | 7,605 | $0.71 | $5,399.55 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 5 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionCommon Stock | 66,477 | $1.93 | $128,300.61 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 4 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionCommon Stock | 10,463 | $1.93 | $20,193.59 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 3 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,209 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionCommon Stock | 17,236 | $0.64 | $11,031.04 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 2 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 18:34 UTC |
Edris BadreddinDirector
|
Exercise / conversionCommon Stock | 13,690 | $0.39 | $5,339.10 |
DisclosureSEC source: 0001786966-26-000001 · primarydocument.xml · nonDerivative · entry 1 Edris Badreddin · CIK 0001786966 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.